Hengrui Pharma seals global collaboration and licensing deal with Bristol-Myers Squibb

The latest update is out from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ).

Jiangsu Hengrui Pharmaceuticals has entered into Global Strategic Collaboration and License Agreements with Bristol-Myers Squibb, marking a new phase of cross-border cooperation between the Chinese drugmaker and the U.S. pharmaceutical group. The deals are designed to advance Hengrui’s products and technologies through BMS’s global network, underscoring Hengrui’s push to internationalize its innovation assets.

The company said the contemplated transactions under the agreements may qualify as notifiable transactions under Hong Kong’s listing rules, but current percentage ratios remain below the 5% threshold, so no formal discloseable transaction classification is triggered. Management cautioned that completion depends on satisfaction or waiver of conditions precedent, and advised shareholders and potential investors to exercise care when dealing in the company’s shares while the collaboration progresses.

The most recent analyst rating on (HK:1276) stock is a Buy with a HK$92.00 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.

More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H

Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a China-based pharmaceutical company listed in Hong Kong and Shanghai, focusing on the research, development and commercialization of innovative medicines. The company operates in the global biopharmaceutical industry and collaborates with multinational drugmakers to expand its international presence and pipeline reach.

Average Trading Volume: 3,140,636

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$401.9B

Find detailed analytics on 1276 stock on TipRanks’ Stock Analysis page.